Institution
University of Modena and Reggio Emilia
Education•Modena, Italy•
About: University of Modena and Reggio Emilia is a education organization based out in Modena, Italy. It is known for research contribution in the topics: Population & Medicine. The organization has 8179 authors who have published 22418 publications receiving 671337 citations. The organization is also known as: Università degli Studi di Modena e Reggio Emilia & Universita degli Studi di Modena e Reggio Emilia.
Topics: Population, Medicine, Cancer, Context (language use), Computer science
Papers published on a yearly basis
Papers
More filters
••
University of Basel1, University Hospital of Basel2, University of Paris3, Pierre-and-Marie-Curie University4, Aarhus University Hospital5, Hochschule Hannover6, Universidade Federal de Minas Gerais7, Shanghai Jiao Tong University8, Université Paris-Saclay9, University of Rochester10, University of Liège11, University of Groningen12, Utrecht University13, Cardiovascular Institute of the South14, University of Modena and Reggio Emilia15, China-Japan Friendship Hospital16, Monash University17, University of Copenhagen18, Copenhagen University Hospital19, Medisch Spectrum Twente20, Vanderbilt University Medical Center21, McMaster University22
TL;DR: Widespread implementation of procalcitonin protocols in patients with acute respiratory infections has the potential to improve antibiotic management with positive effects on clinical outcomes and on the current threat of increasing antibiotic multiresistance.
Abstract: Summary Background In February, 2017, the US Food and Drug Administration approved the blood infection marker procalcitonin for guiding antibiotic therapy in patients with acute respiratory infections. This meta-analysis of patient data from 26 randomised controlled trials was designed to assess safety of procalcitonin-guided treatment in patients with acute respiratory infections from different clinical settings. Methods Based on a prespecified Cochrane protocol, we did a systematic literature search on the Cochrane Central Register of Controlled Trials, MEDLINE, and Embase, and pooled individual patient data from trials in which patients with respiratory infections were randomly assigned to receive antibiotics based on procalcitonin concentrations (procalcitonin-guided group) or control. The coprimary endpoints were 30-day mortality and setting-specific treatment failure. Secondary endpoints were antibiotic use, length of stay, and antibiotic side-effects. Findings We identified 990 records from the literature search, of which 71 articles were assessed for eligibility after exclusion of 919 records. We collected data on 6708 patients from 26 eligible trials in 12 countries. Mortality at 30 days was significantly lower in procalcitonin-guided patients than in control patients (286 [9%] deaths in 3336 procalcitonin-guided patients vs 336 [10%] in 3372 controls; adjusted odds ratio [OR] 0·83 [95% CI 0·70 to 0·99], p=0·037). This mortality benefit was similar across subgroups by setting and type of infection (p interactions >0·05), although mortality was very low in primary care and in patients with acute bronchitis. Procalcitonin guidance was also associated with a 2·4-day reduction in antibiotic exposure (5·7 vs 8·1 days [95% CI −2·71 to −2·15], p vs 22%, adjusted OR 0·68 [95% CI 0·57 to 0·82], p Interpretation Use of procalcitonin to guide antibiotic treatment in patients with acute respiratory infections reduces antibiotic exposure and side-effects, and improves survival. Widespread implementation of procalcitonin protocols in patients with acute respiratory infections thus has the potential to improve antibiotic management with positive effects on clinical outcomes and on the current threat of increasing antibiotic multiresistance. Funding National Institute for Health Research.
304 citations
••
TL;DR: In this article, a theoretical framework for explaining consumer word of mouth and protest behaviors against corporate irresponsibility is developed and tested through field surveys with adult consumers, demonstrating how consumers' negative moral emotional responses to corporate infractions instigate, in combination with other-regarding virtues, negative word-of-mouth and protest toward the corporation.
302 citations
••
TL;DR: This review will focus on recent advances and views on the role that modifications of cell signalling and remodelling of the immune response play during human aging and longevity, paying particular attention to phenomena which are linked to the so called inflammaging process.
Abstract: Major advances in preventing, delaying, or curing individual pathologies are responsible for an increasingly long life span in the developed parts of our planet, and indeed reaching eight to nine decades of life is nowadays extremely frequent. However, medical and sanitary advances have not prevented or delayed the underlying cause of the disparate pathologies occurring in the elderly: aging itself. The identification of the basis of the aging processes that drives the multiple pathologies and loss of function typical of older individuals is a major challenge in current aging research. Among the possible causes, an impairment of the immune system plays a major role, and indeed numerous studies have described immunological changes which occur with age. Far from the intention of being exhaustive, this review will focus on recent advances and views on the role that modifications of cell signalling and remodelling of the immune response play during human aging and longevity, paying particular attention to phenomena which are linked to the so called inflammaging process, such as dysregulation of innate immunity, altered T-cell or B-cell maturation and differentiation, as well as to the implications of immune aging for vaccination strategies in the elderly.
301 citations
••
TL;DR: It is demonstrated that both in vivo and in vitro STAT3 is the key transcription factor responsible for IL-6 activation of hepcidin gene expression in the liver.
301 citations
••
TL;DR: A suite of complementary tests will inform crucial decisions by healthcare providers and policy makers and understanding their strengths and limitations will be critical to their judicious application for the development of algorithmic approaches to treatment and public health strategies.
Abstract: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated coronavirus disease 2019 (COVID-19) pandemic has demanded rapid upscaling of in-vitro diagnostic assays to enable mass screening and testing of high-risk groups, and simultaneous ascertainment of robust data on past SARS-CoV-2 exposure at an individual and a population level. To meet the exponential demand in testing, there has been an accelerated development of both molecular and serological assays across a plethora of platforms. The present review discusses the current literature on these modalities, including nucleic acid amplification tests, direct viral antigen tests and the rapidly expanding laboratory-based and point of care serological tests. This suite of complementary tests will inform crucial decisions by healthcare providers and policy makers, and understanding their strengths and limitations will be critical to their judicious application for the development of algorithmic approaches to treatment and public health strategies.
300 citations
Authors
Showing all 8322 results
Name | H-index | Papers | Citations |
---|---|---|---|
Carlo M. Croce | 198 | 1135 | 189007 |
Gregory Y.H. Lip | 169 | 3159 | 171742 |
Geoffrey Burnstock | 141 | 1488 | 99525 |
Peter M. Rothwell | 134 | 779 | 67382 |
Claudio Franceschi | 120 | 856 | 59868 |
Lorenzo Galluzzi | 118 | 477 | 71436 |
Leonardo M. Fabbri | 109 | 566 | 60838 |
David N. Reinhoudt | 107 | 1082 | 48814 |
Stefano Pileri | 100 | 635 | 43369 |
Andrea Bizzeti | 99 | 1168 | 46880 |
Brian K. Shoichet | 98 | 281 | 40313 |
Dante Gatteschi | 97 | 727 | 48729 |
Roberta Sessoli | 95 | 424 | 41458 |
Thomas A. Buchholz | 93 | 494 | 33409 |
Pier Luigi Zinzani | 92 | 857 | 35476 |